Strong association between hyperferritinaemia and metastatic disease in nasopharyngeal carcinoma

European Journal of Cancer Part B: Oral Oncology

Volumn 32, Issue 4, 1996, Pages 242-245

  Ho, S ^a   Leung, S F ^a   Leung, W T ^a   Tsao, S Y ^a,b   Kwan, W H ^a   Choi, P ^a   Johnson, P J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b GLENEAGLES HOSPITAL   (Singapore)

Author keywords

Hyperferritinaemia; Metastatic; Nasopharyngeal carcinoma

Indexed keywords

FERRITIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NASOPHARYNX CARCINOMA; PREDICTION; PRIORITY JOURNAL;

EID: 0030200882     PISSN: 09641955     EISSN: None     Source Type: Journal    
DOI: 10.1016/0964-1955(95)00084-4     Document Type: Article

References (16)

1. 1. Jacobs A, Miller F, Worwood M. Ferritin in serum, clinical and biochemical implication. N Engl J Med 1975, 292, 951-956.
2. 2. Worwood M. Ferritin in human tissues and serum. Clin Haematol 1982, 11, 275-307.
3. 3. Jacobs A. Serum ferritin and malignant tumours. Med Oncol Tumour Pharmacother 1984, 1, 149-156.
4. 4. Maxim PE, Veltri RW. Serum ferritin as a marker in patients with squamous cell carcinoma of the head and neck. Cancer 1986, 57, 305-311.
5. 5. Ho JHC. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978, 4, 183-198.
6. 6. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carinoma. Int J Cancer 1976, 17, 1-7.
7. 7. Henle W, Ho JHC, Henle G, Chan JCW, Kwan HC. Nasopharyngeal carcinoma: significance of changes of Epstein-Barr virus-related antibody patterns following therapy. Int J Cancer 1977, 20, 663-672.
8. 8. Lymn TC, Hsu MM, Hsieh T, Tu SM. Prognosis of nasopharyngeal carcinoma by Epstein-Barr virus antibody titre. Arch Otolaryngol 1977, 103, 128-132.
9. 9. De-Vathaire F, Sancho-Garnier H, De-The H, et al. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multicentre follow-up study. Int J Cancer 1988, 42, 176-181.
10. 10. Lynn TC, Tu SM, Kawamura A, Jr. Long-term follow-up of IgG and IgA antibodies against viral capsid antigens of Epstein-Barr virus in nasopharyngeal carcinoma. J Laryngol Otol 1985, 99, 567-572.
11. 11. Marcus DM, Zinberg N. Measurement of serum ferritin by radioimmunoassay: results in normal individuals and patients with breast cancer. J Natl Cancer Inst 1975, 55, 791-795.
12. 12. Jacobs A, Slater A, Whittaker JA, Canelloo G, Wiernik PH. Serum ferritin concentration in untreated Hodgkin's disease. Br J Cancer 1976, 34, 162-166.
13. 13. Melia WM, Bullock S, Johnson PJ, Williams R. Serum ferritin in hepatocellular carcinoma: a comparison with alpha-fetoprotein. Cancer 1983, 51, 2112-2115.
14. 14. Szymendera JJ, Kozlowicz-Gudzinska I, Madej G, Sikorowa L, Kaminska JA, Kowalska M. Clinical usefulness of serum ferritin measurements in patients with testicular germ cell tumours. Oncology 1985, 42, 253-258.
15. 15. Pattanapanyasat K, Hoy TG, Jacobs A, Courtney S, Webster DJT. Ferritin-bearing T-lymphocytes and serum ferritin in patients with breast cancer. Br J Cancer 1988, 57, 193-197.
16. 16. Altun M, Fandi A, Dupuis O, Cvitkovic E, Krajina Z, Eschwege F. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 1995, 32, 859-877.